Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Karis
Observed name:
D. Karis
Institution:
AstraZeneca (Sweden)
Observed institution:
AstraZeneca (Sweden)
OpenAlex ID:
A5084882003
Direct AMP-activated protein kinase activators: a review of evidence from the patent literature
2012
·
Fabrizio Giordanetto
, David Karis
·
Expert Opinion on Therapeutic Patents
·
71
Creating Novel Activated Factor XI Inhibitors through Fragment Based Lead Generation and Structure Aided Drug Design
2015
·
Ola Fjellström
, Sibel Akkaya
, et al.
·
PLoS ONE
·
43
PDF
A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5)
2006
·
Peter Bach
, Karolina Nilsson
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
32
Structure–activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGluR5)
2006
·
Peter Bach
, Karolina Nilsson
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
22
Fragment Screening of Soluble Epoxide Hydrolase for Lead Generation—Structure‐Based Hit Evaluation and Chemistry Exploration
2016
·
Yafeng Xue
, Thomas Olsson
, et al.
·
ChemMedChem
·
19
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
2014
·
J. Sandmark
, L. Oster
, et al.
·
Worldwide Protein Data Bank
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
2014
·
J. Sandmark
, L. Oster
, et al.
·
Worldwide Protein Data Bank
Show more works
View as search
Works count:
14
Citation count:
187
H-index:
5
I10-index:
5
Year
Topic
Type